Tokyo, Japan

Tadatsugu Taniguchi

This inventor holds 23 USPTO granted patents and 1 published patent application, plus 6 CIPO patents and 1 EPO patent, primarily in Cancer Immunotherapy. Top assignees: Juridical Foundation, Japanese Foundation for Cancer Research, Ajinomoto Co., Ltd., Boehringer Ingelheim International Gmbh. Active years: 1987-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tadatsugu Taniguchi. Retrieved from https://idiyas.com/inventor/tadatsugu-taniguchi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 

% Patents Active = 100.0



Average Co-Inventor Count = 3.1

ph-index = 11

Forward Citations = 356(Granted Patents)


Location History:

  • Ibaraki, JP (1989 - 2001)
  • Tokyo, JP (1987 - 2016)

Company Filing History:


Years Active: 1987-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Tumor Immune Microenvironment
Immunotherapy
Recombinant DNA
Gene Expression
Interleukin-2
HMGB Protein
IRF-1
Human Interferon
Diagnostic Methods
Recombinant Protein
23 patents (USPTO):Explore Patents

Title: Innovations of Tadatsugu Taniguchi: A Leader in Molecular Biology

Introduction: Tadatsugu Taniguchi is a prominent inventor based in Tokyo, Japan, known for his groundbreaking contributions to molecular biology. With a remarkable portfolio consisting of 22 patents, he has made significant strides in understanding immune responses and genetic engineering. His work is recognized both nationally and globally, affecting various fields, including cancer research and biotechnology.

Latest Patents: Among his latest innovations is a patent related to DNA and recombinant plasmid technology. This invention discloses a recombinant plasmid encompassing at least the entire coding region of human fibroblast interferon messenger RNA, alongside methods for preparing such plasmid. Another noteworthy patent focuses on the inhibitor of HMGB protein-mediated immune response activation. This invention provides an inhibitor that contains at least one compound from a specific group, including phosphorothioate oligonucleotides, and outlines a method for screening inhibitors or enhancers of immune response activation mediated by HMGB proteins.

Career Highlights: Throughout his career, Taniguchi has been affiliated with several notable organizations. He worked at the Juridical Foundation, the Japanese Foundation for Cancer Research, and Ajinomoto Co., Ltd. His roles in these institutions have contributed to advancing his research and enhancing the impact of his inventions.

Collaborations: Taniguchi has collaborated with various esteemed colleagues, including Haruo Sugano and Masami Muramatsu. These partnerships have allowed for the exchange of ideas and acceleration of research, driving forward their collective goals in the field of molecular biology.

Conclusion: Tadatsugu Taniguchi's contributions to science through his innovations and patents reflect his dedication to advancing molecular biology. His continued efforts are expected to inspire future generations of inventors and researchers, paving the way for further discoveries in the realms of genetics and immunology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…